Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (7,660,795)	$ (5,517,660)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,314,584	1,334,267
Share based compensation	422,266	311,406
Loss on disposition of assets	60,264	1,959
(Increase) decrease in operating assets:
Accounts receivable, net	358,258	(154,292)
Other assets	(674,539)	251,976
Security deposits	36,357	86,081
Increase (decrease) in operating liabilities:
Accounts payable and accrued expenses	147,815	(518,074)
Patient deposits	254,696	183,987
Net cash used in operating activities	(5,741,094)	(4,020,350)
Cash flows from investing activities:
Purchase of property and equipment	(371,882)	(52,626)
Purchase of license fee		(243,750)
Brand development	(66,495)
Acquisitions (Note 6)	(731,909)	(200,000)
Proceeds from sale of fixed assets	14,450
Net cash used in investing activities	(1,155,836)	(496,376)
Cash flows from financing activities:
Proceeds from issuance of common stock	19,005,323	3,736,613
Proceeds from notes payable		2,891,520
Payments on notes payable	(3,517,195)	(737,758)
Payments of debt issuance costs		(70,000)
Payments on finance lease obligation	(20,828)	(13,034)
Net cash provided by financing activities	15,467,300	5,807,341
Net increase in cash	8,570,370	1,290,615
Cash, beginning of period	2,623,952	373,689
Cash, end of period	11,194,322	1,664,304
Supplemental cash flow information:
Interest paid	219,573	63,152
Non cash financing and investing:
Debt discount notes payable		115,000
Debt payment by sale of property and equipment		$ 1,232,500